The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Triple negative breast cancer: Pitfalls and progress
Open accessAbstract
Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and progesterone receptor expression and lacks HER2 overexpression or gene amplification. It accounts for 10–15% of incident breast cancers and carries the worst prognosis. TNBC is overrepresented among Black and pre-menopausal women and is associated with significant psychological and treatment-related burdens, including financial toxicity. Like other breast cancers, TNBC is biologically heterogeneous, leading to diverse clinical and epidemiological behaviors, however, unlike the other clinical subtypes, in TNBC we still lack tumor-specific targeted therapy. Early TNBC outcomes have improved due to the intensification of therapies, including improvements in polychemotherapy and the addition of immunotherapy. Future efforts are needed to identify targetable aberrations for specific drug therapy, prevent immune evasion, and increase social-economic support. Given that the name TNBC illustrates its lack of specifically targeted and effective therapy, we look forward to being able to retire the name in favor of a group of targetable entities within what is now called “TNBC”.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Targeted immunotherapy for HER2-low breast cancer with 17p loss
Li, Y., Sun, Y., Kulke, M., Hechler, T., der Jeught, K. V., Dong, T., He, B., Miller, K. D., Radovich, M., Schneider, B. P., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc6894 · Cited by 37
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Cited by
Hachey, S. J., Hatch, C. J., Gaebler, D., Mocherla, A., Nee, K., Kessenbrock, K., & Hughes, C. C. W. (2024) · Breast Cancer Research · doi:10.1186/s13058-023-01760-y · Cited by 24
Xue, Y., Wang, Q., Chen, Y., Zhang, X., Tang, J., Liu, Y., & Liu, J. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202403998 · Cited by 14
Biagiotti, G., Cazzoli, R., Andreozzi, P., Aresta, G., Francesco, M., Mangini, C., di Gianvincenzo, P., Tobia, C., Recchia, S., Polito, L., et al. (2024) · Nanoscale Horizons · doi:10.1039/d4nh00042k · Cited by 11
Chen, S.-F., Ng, P.-L., Lai, C.-W., Wang, F.-J., Wang, Y.-C., Chen, M.-H., Tung, F.-I., & Liu, T.-Y. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03187-3 · Cited by 11
Metadata
- Authors
- Zagami, P., & Carey, L. A.
- Venue
- npj Breast Cancer
- Published
- 2022-08-20
- Volume
- 8
- Issue
- 1
- Pages
- 95-95
- ISSN
- 2374-4677 (ISSN-L)
- OpenAlex
- W4292415327
- Cited by
- 839
- References
- 88
- FWCI
- 50.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Triple negative breast cancer: Pitfalls and progress. https://app.cochat.ai/papers/10.1038/s41523-022-00468-0
- The paper
- Zagami, P., & Carey, L. A. (2022). Triple negative breast cancer: Pitfalls and progress. npj Breast Cancer. https://doi.org/10.1038/s41523-022-00468-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.